Double-Barreled CAR-T takes aim at Hard-to-Treat myeloma
NCT ID NCT07249073
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether a new type of CAR-T cell therapy that targets two proteins (CD19 and BCMA) on myeloma cells is safe for people whose cancer has returned or stopped responding to treatment. Nine participants will receive the therapy and be monitored for side effects and signs of tumor shrinkage. The goal is to find the safest dose and see if the approach can control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact